In 2023, significant advancements were made in the treatment of locally advanced (LACC) and advanced cervical cancer (aCC). The INTERLACE trial demonstrated that induction chemotherapy before concurrent chemoradiation (CCRT) improved progression-free survival (PFS) and overall survival (OS) in LACC patients. The KEYNOTE-A18 trial showed that adding pembrolizumab to CCRT improved PFS, although OS data were not yet mature. These findings have led to updated treatment algorithms for LACC. For aCC, the KEYNOTE-826 trial established pembrolizumab combined with paclitaxel-platinum chemotherapy as a preferred first-line treatment, while the BEATcc trial offered an alternative with atezolizumab, paclitaxel-platinum, and bevacizumab. The innovaTV301 trial confirmed the efficacy of tisotumab vedotin in aCC, showing improved OS and PFS compared to chemotherapy. Trastuzumab deruxtecan also showed promise in HER2-expressing aCC. Future directions include exploring ADCs, passive and active immunotherapies, and combination therapies. Research is ongoing to optimize the use of immunotherapy and ADCs in cervical cancer, with a focus on improving outcomes for patients with persistent, recurrent, or metastatic disease. The role of PD-L1 inhibition and the need for further studies on immune checkpoint inhibitor rechallenge remain important areas of investigation. The gynecologic oncology community is also working to address unmet needs in rare cervical cancer subtypes and to expand access to novel therapies in low- and middle-income countries.In 2023, significant advancements were made in the treatment of locally advanced (LACC) and advanced cervical cancer (aCC). The INTERLACE trial demonstrated that induction chemotherapy before concurrent chemoradiation (CCRT) improved progression-free survival (PFS) and overall survival (OS) in LACC patients. The KEYNOTE-A18 trial showed that adding pembrolizumab to CCRT improved PFS, although OS data were not yet mature. These findings have led to updated treatment algorithms for LACC. For aCC, the KEYNOTE-826 trial established pembrolizumab combined with paclitaxel-platinum chemotherapy as a preferred first-line treatment, while the BEATcc trial offered an alternative with atezolizumab, paclitaxel-platinum, and bevacizumab. The innovaTV301 trial confirmed the efficacy of tisotumab vedotin in aCC, showing improved OS and PFS compared to chemotherapy. Trastuzumab deruxtecan also showed promise in HER2-expressing aCC. Future directions include exploring ADCs, passive and active immunotherapies, and combination therapies. Research is ongoing to optimize the use of immunotherapy and ADCs in cervical cancer, with a focus on improving outcomes for patients with persistent, recurrent, or metastatic disease. The role of PD-L1 inhibition and the need for further studies on immune checkpoint inhibitor rechallenge remain important areas of investigation. The gynecologic oncology community is also working to address unmet needs in rare cervical cancer subtypes and to expand access to novel therapies in low- and middle-income countries.